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ABSTRACT
Medically, the oil-in-water nanosized emulsions are used mainly as delivery carriers for lipophilic
drug molecules which show therapeutic activity when administered via parenteral, ocular and
transdermal routes. To extract multifunctional activities, the nanosized emulsions containing neutral,
anionic and cationic charges over dispersed oil droplets are designed with the help of variety of
excipients especially emulsifiers. This type of decoration on the dispersed oil droplet’s surface allows
the nanosized emulsions to be useful for drug delivery and/or drug targeting to otherwise
inaccessible internal organs of human body. The aim of this review is to address the various
manufacturing techniques and excipients used during the formulation of the multifunctional o/w
nanosized emulsions for medical applications.
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INTRODUCTION 
Nanosized or submicron emulsions can be
defined as systems of at least two nearly
immiscible fluids dispersed one into another in
the form of droplets with diameter significantly
below one micrometer. Production of
nanosized emulsions is achieved for diameters
ranging from 50-400 nm and a narrow droplet
size distribution (1). Medically, the oil-in-water
(o/w) nanosized emulsions are used mainly as
delivery  carriers for  lipophilic  drug  molecules 
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which show therapeutic activity when
administered via parenteral, ocular and
transdermal routes. 
To extract multifunctional activities, the
nanosized emulsions containing neutral, anionic
and cationic charges across the surface of the
dispersed oil droplets are designed with the
help of variety of excipients, especially
emulsifiers. Surface charge optimization allows
the o/w nanosized emulsions to be useful for
drug delivery and/or targeting to otherwise
inaccessible internal organs of the human
body (2).
In contrast to microemulsions, the o/w
nanosized emulsions are thermodynamically
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instable, which can significantly reduce their
applicability. The thermodynamic instability
behaviour of emulsions include phenomena
such as flocculation, coalescence, creaming, and
Ostwald ripening. The physical instability of
emulsions is due to the spontaneous tendency
toward a minimal interfacial area and hence a
minimal surface free energy between the
dispersed phase and the dispersion medium.
Minimizing the interfacial area is mainly
achieved by two mechanisms: first coagulation
possibly followed by coalescence and second by
Ostwald ripening. Coalescence is often
considered as the most important
destabilization mechanism leading to coursing
of dispersions and can be prevented by a
careful choice of stabilizers or emulsifiers. The
molecular diffusion of solubilizate (Ostwald
ripening), however, will occur as soon as curved
interfaces are present. During Ostwald
ripening, the molecular diffusion of the
lipophilic components occurs from small
particles to larger particles due to the difference
in escaping tendency (vapor pressure) between
the two. Ostwald ripening is thus directly
proportional to the solubility of the lipophilic
component in the dispersion medium as well as
dependent on the particle size distribution.
Various physical factors such as density
difference between the dispersion medium and
droplets, strong hydrodynamic agitation,
interdroplet interaction, and the droplet
interfacial visco-elasticity can affect or perturb
the colloidal stability of emulsion droplets and
thus their shelf life and therapeutic utility.
Therefore, the stabilization of emulsion
droplets is in many cases very important and
desirable. There are different ways of
stabilization of the o/w nanosized emulsions,
all of which are related to the modification of
the interface between the dispersion medium
and emulsion droplets. Depending on the
intended medical application of nanosized
emulsions, various kinds of emulsifier
molecules ranging from small surfactants or
surface-active polymers to polylayered
i n t e r f a c i a l  c o a t i n g s  p r o d u ced  b y
multicomponent emulsifier films are
considered.   
This review encompasses a short overview on
the preparation of medically useful o/w
nanosized emulsions followed by a description
(examples) of selected emulsifier molecules
used for emulsion stabilization. Moreover, it is
emphasized that the review focuses only on
nanosized emulsions (having size distribution
ranging between 50 and 1000 nm with a mean
droplet size of about 250 nm), which should
not be confused with self-microemulsifying
drug delivery systems or microemulsions that
are transparent, thermodynamically stable
dosage forms. Before proceeding, a brief
description concerning classification of
nanosized emulsions is presented. 
CLASSIFICATION OF O IL-IN-W ATER
NANOSIZED EMULSIONS
Based on the emulsifier combinations used in
the formation of submicron emulsion droplets,
the o/w nanosized emulsions can be classified
into three types (Figure 1). Emulsifiers with the
capacity to produce a negative charge at the
o/w interface are termed anionic and those able
to provide a positive charge at the o/w
interface are called cationic. The literature
suggests that neither triglycerides nor
phospholipidic emulsifier’s components of the
conventional or anionic emulsions are able to
significantly sustain the incorporated lipophilic
drug release in simulated or real physiological
environments under sink conditions. Therefore,
in an attempt to prolong and/or optimize the
drug release, cationic lipid or polysaccharide
emulsifiers are added to the emulsions to elicit
mucoadhesion with anionic ocular tissues by an
electrostatic adhesion. Indeed, cationic
emulsions prepared using stearylamine,
oleyamine and chitosan can serve this purpose.
It was initially believed and now has become
clearer from many reports in the literature that
an occurrence of electrostatic attraction
between the cationic emulsified droplets and
anionic cellular moieties of the ocular and
topical skin surface tissues enhance the
bioavailability of emulsions containing
lipophilic drugs (3-6). There is another type of
emulsion that is neutral in terms of the charge
on the dispersed droplets. These are instead
stabilized through steric effects exerted by the
emulsifier molecule present in the emulsion
formulation.
According to Capek (7), the stability of the
electrostatically- and sterically-stabilized o/w
nanosized emulsions can be controlled by the
charge of the electrical double layer and the
thickness of the droplet surface layer formed by
non-ionic emulsifier, respectively. In spite of
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the similarities between electrostatically- and
sterically-stabilized emulsions, there are large
differences in the partitioning of molecules of
ionic and non-ionic emulsifiers between the oil
and water phases and the thickness of the
interfacial layers at the droplet surface (7). The
thin interfacial layer (the electrical double layer)
at the surface of electrostatically stabilized
droplets does not create any steric barrier for
mass transfer. This may not necessarily be true
for the thick interfacial layer formed by a non-
ionic emulsifier. The sterically-stabilized oil
droplets, however, can favor the transfer of
materials within the intermediate agglomerates.
Hence, the stability of electrosterically-
kstabilized emulsion (ä ) is controlled by the
ratio of the thickness of the non-ionic
emulsifier adsorption layer (ä) to the thickness
of the electrical double layer (k ) around the oil-1
droplets (7).





To get a better idea of how to formulate the
nanosized emulsion delivery systems suitable
for parenteral, ocular, percutaneous, and nasal
uses, the reader is referred to more detailed
descriptions of methods of nanosized emulsion
preparation (8,9). A hot-stage high-pressure
(HP) homogenization technique or combined
emulsification technique (de novo production)
is frequently employed in order to prepare
nanosized emulsions which exhibit the desired
stability characteristics even after subjection of
the emulsion to steam sterilization. Therefore,
the steps involved in this technique in making
placebo (drug-free) neutral, anionic and cationic
emulsions can be arranged in the following
order:
1. Separately weigh the oil- and water- soluble
ingredients.
2. Heat both oil and water phases separately to
70° C.
3. Add the oil phase to the water phase and
continue the heating up to 85° C with
constant stirring to form a coarse emulsion.
4. Mix at high shear to make a fine emulsion.
5. Cool the fine emulsion formed in ice bath.
6. Homogenize the fine emulsion.
7. Cool the homogenized emulsion in ice bath.
8. Filter the emulsion through a filter of
suitable porosity to remove large droplets
or debris.
9. Adjust the emulsion to the desired pH.   
10. Purge nitrogen/argon gas into the head
space of the vials containing the emulsion.
11. Steam Sterilize the emulsion 
The initial heating may be necessary for the
solubilization of the respective oil and water
phase components in their corresponding
phases. Mixing the two phases with constant
mild stirring and subsequently raising the
temperature to 85° C is needed to form an
initial coarse emulsion and to localize the
surfactant molecules for better adsorption at
the oil-water interface, respectively. The
traditional droplet size-reducing steps involved
during the preparation include constant mild
stirring initially mixing oil and water phases,
high shear/speed mixing, followed by
homogenization. High pressure (HP)
homogenizers are particularly suitable for
continuous production of finely dispersed
emulsions and are therefore of interest in the
food and pharmaceutical fields (10-12).
Extreme shear and high energy input have to be
applied during the homogenization process to
fragment the droplets of a coarse emulsion
from the micro- to the nano-scale range,
overcoming thus the Laplace pressure. The
Laplace pressure, which causes the resistance to
interface deformation and breakup, effectively
increases when the droplet diameter decreases,
and is therefore larger for nanosized- than for
coarse emulsions (1).
Figure 1 Classification of oil-in-water (o/w) nanosized
emulsions based on emulsifier molecules.
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Equipment to make nanosized
emulsions
High shear/speed mixing of a coarse emulsion
can be performed using rotor-stator, high
pressure, membrane or ultrasonic devices
(11,13,14). Different equipment using HP
technology are being developed, at both
prototype and industrial scales, depending on
the nominal pressure level. For example, jet
dispersers involve two fluid jets (each from
opposite bores) that collide with one another to
disrupt particles. Marie et al (15) have shown
that it is possible to perform oil-emulsification
by direct injection of the oily phase under
pressure (up to 350 MPa) into a continuous
aqueous phase at low pressure. Nevertheless
the oil droplets created by such a process
displayed large size distributions, indicating that
a more precise control of  process and
optimization may be required using this
process. 
To produce emulsions with small droplet size,
microfluidization or HP homogenization is
usually used. Microfluidization is a process
whereby a liquid mixture is forced by high
pressure through an interaction chamber, which
splits the stream into two and then recombines
them at ultrahigh velocities (16). The product
can be recycled to reduce droplet size further.
The combination of high shear, turbulence, and
cavitation generated by this apparatus can
produce nanosized or submicrometer
emulsions with a narrow size distribution (17).
For instance, Microfluidizer devices
(Microfluidics™) comprise interaction
chambers designed with a microchannel
architecture that combines laminar extension
flow at the inlet of the chamber to turbulent
flow with cavitation and impact in and at the
outlet of the chamber (10,14,18,19): the premix
stream is divided into two fluid jets at the inlet
of the chamber and the fluid velocity is
accelerated due to a sudden decrease in the pipe
diameter. Laminar extension flow is considered
responsible for droplet disruption at the inlet of
the chamber. Inside the chamber, the fluid
changes its flow direction leading to enhanced
particle collision and impingement on the
chamber walls. The fluid jets then collide
(coming from two opposite microchannels)
leading to enhanced particle disruption.
Another HP mixing equipment of interest is
Polytron™ which also functions on a similar
principle. 
In HP homogenization, fluid is forced at high
pressure by means of a plunger pump through a
very narrow channel. Depending on the type of
homogenizer, the fluid may then collide head
on with another high velocity stream or hit a
hard-impact ring. Droplet size is reduced by
cavitation, high shear forces, and high-speed
collisions with other droplets (20). Pressure,
temperature, and number of passes are
parameters that can be controlled and influence
the efficiency and magnitude of droplet size
reduction. HP-homogenizers of piston-gap type
developed by manufacturers such as Avestin™,
APV™ or Stansted Fluid Power™ consist of
one or two piston intensifier(s) able to generate
high pressure, and HP-valve equipped with
ceramic needles and seat of specially engineered
design. In such HP-homogenizers, the fluid
under pressure is forced through a small orifice
of some micrometers width, the HP-valve gap
(21). The fluid accelerates over a very short
distance to very high velocity and the resulting
strong pressure gradient between the inlet and
outlet of the HP-valve generates intense shear
forces and extensional stress through the valve
gap (22). Cavitation, turbulence and impact
with solid surfaces takes place at the outlet of
the valve gap (23,24). Due to shear effects and
conversion of kinetic energy into heat, the fluid
travelling through the HP-valve is accompanied
by short-life heating phenomena that can be
controlled by efficient cooling devices (25,26).
All these mechanical forces are expected to
disrupt particles down to the submicron range.
This type of equipment can deliver pressure up
to  1 5 0 - 2 0 0  M P a  ( h i g h  p r e s su r e
homogenization, HPH) and even more for the
latest developments, i.e. up to 300-400 MPa for
ultra-high pressure homogenization (UHPH).
On the basis of a numerical simulation, Floury
et al (24) attempted to understand the flow
pattern of oil-in-water emulsions (20%, w/w,
sunflower oil) stabilized by Tween 20 (1%,
w/w) in UHP-homogenizer. Their results
suggested that: (i) extensional flow taking place
before and in the HP-valve gap probably led to
droplet deformation and breakup; (ii)
turbulence, recirculation and cavitation
phenomena taking place at the outlet and
downstream of the HP-valve gap could
contribute to additional breakup but also to re-
coalescence of oil droplets.
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Approaches to incorporate drug into oil
phase or at the oil-water interface
There are four different approaches (27) to
incorporate lipophilic drugs or heat labile
molecules into the oil phase or at the o/w
interface of the nanosized emulsions:
(A) extemporaneous drug addition, 
(B) de novo emulsion preparation, 
(C) an interfacial incorporation approach,
which includes the recently developed
SolEmul  technology, and ®
(D) incorporation of antibodies, DNA protein,
oligonucleotide or heat labile molecules
(A) extemporaneous drug addition
Cohen et al (28), when looking for a new
galenic presentation form for amphotericin B
with better ocular tolerance over the
commercially available Fungizone® eye drops,
incorporated the drug directly into the
preformed 20% emulsion, Intralipid .®
However, after addition of the solid drug
particles or drug solution, several physical
changes such as phase separation, precipitation
or creaming may occur thus limiting such
practices in o/w nanosized emulsion
preparations. Therefore, ocular active lipophilic
agents are not normally incorporated into the
emulsions by this extemporaneous addition
method.
(B) de novo emulsion preparation
In principle, the lipophilic drug molecules
(thermostable) should however be incorporated
by a de novo process as described earlier. Thus,
the drug is initially solubilized or dispersed
together with an emulsifier in suitable single-oil
or oil mixture by means of heating. The water
phase containing the osmotic agent with or
without an additional emulsifier is also heated
and mixed with the oil phase by means of high-
speed mixers. Further homogenization takes
place to obtain the needed small droplet size
range of the emulsion. A terminal sterilization
by filtration, or steam, then follows. The
emulsion thus formed contains most of the
drug molecules within its oil phase or its oil-
water interface. This is a generally accepted and
standard method to prepare lipophilic drug-
loaded nanosized emulsions for parenteral,
ocular, percutaneous, and nasal uses, as
illustrated in Figure 2. This process is normally
carried out under aseptic conditions and
nitrogen or argon atmosphere to prevent both
contamination and potential oxidation of
sensitive excipients.
(C) Interfacial incorporation approach
Since many drugs of commercial interest
generally have a solubility that is too low in
FDA approved oils, Lance et al (29) proposed a
method to incorporate such drugs into the
interfacial o/w layer of the emulsion droplets.
This can be achieved by initially dissolving the
drug along with the phospholipid (emulsifier) in
an organic solvent, instead of in the oil.
Following the solvent evaporation, the obtained
phospholipids/drug co-mixture is used in the
de novo production of the emulsions (30).
However, this approach suffers from possible
drug nanocrystal formation and from the use of
organic solvent during the emulsion
preparation process. To overcome such
drawbacks, a novel SolEmul  technology was®
developed in which an additional high speed
homogenization step is included to mix the
drug with emulsion. The drug particles are
micronized to the nanosize range prior to
incorporation into the emulsion. By this
technique, adequate amounts of lipophilic drugs
can be substantially incorporated into the
Figure 2 Preparation of o/w nanosized emulsion (de
novo method) [by permission from Elsevier (27)].
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lipophilic core or intercalated between the
selected emulsifier molecular films at the o/w
interface of the emulsions. The drugs reported
to have been incorporated by this novel
approach are amphotericin B, carbamazepine
and itraconazole (31-34). However, it should be
emphasized that all the lipophilic drug
molecules that have been incorporated into the
emulsions by SolEmul  technology are meant®
only for parenteral use (31-34) and so far no
ocular, nasal and topical active agents have been
incorporated by this approach although there
appears to be no regulatory reason to exclude
this technical improvement when designing
emulsion formulations for these applications.
(D) incorporation of antibodies, DNA protein,
oligonucleotide or heat labile molecules
Both extemporaneous drug addition (method
A) into the preformed emulsion and de novo
emulsion preparation (method B) are useful for
the incorporation of heat labile molecules into
the o/w nanosized emulsions. For example,
cyclosporin A was successfully incorporated
without drug degradation into the emulsion by
following the de novo method (35). The
extemporaneous addition of the solid drug or
drug previously solubilized in another solvent
or oil to the o/w nanosized emulsions is not a
favoured approach as it might compromise the
integrity of the emulsion. However, since
therapeutic DNA and single stranded
oligonucleotides (oligos) or siRNA are water
soluble due to their polyanionic character, the
aqueous solution of these compounds can be
added directly to the o/w cationic nanosized
emulsion in order to interact electrostatically
with the cationic emulsion droplets and thus
associate/link superficially at the oil-water
interface of the emulsion (36-38). When
administered via parenteral and ocular routes,
the release of the DNA and oligos from the
associated emulsion droplet surfaces should
therefore initially be dependent on the affinity
between the physiological anions of the
biological fluid and cationic surface of the
emulsion droplets. The mono- and di-valent
anions in the biological fluid available in
parenteral route is plasma and in ocular topical
route is tear fluid, aqueous humor and vitreous.
Moreover, these biofluids contain multitude of
macromolecules and nucleases. There is a
possibility that endogenous negatively charged
biofluid’s components could dissociate the
DNA and oligos from cationic emulsion. It is
noteworthy to conduct during the
preformulation development stages an in vitro
release study for therapeutic DNA and oligos-
containing cationic nanoemulsion in these
biological fluids and this type of study could be
considered as an indicator for the strength of
the interaction occurring between DNA or
oligo and the emulsion (39). Interestingly, the
stability of oligos (a 17-bases oligonucleotide,
partially phosphorothioated) was validated
using a gel-electrophoresis method. After
incorporating the oligos into the cationic
nanosized emulsion as well as during in vitro
experiments of oligo-containing emulsion in
vitreous fluid at different time periods, the
emulsions were phase separated by Triton X-
100 and then the degradation of oligos was
monitored using gel-electrophoresis (39). No
appearance of new bands was observed in
comparison to the standard aqueous oligos
solution. This result indicated that the oligos
did not undergo degradation under the
conditions applied to prepare a sterile emulsion. 
In order to enable the nanosized emulsion to
target inaccessible  t issues ,  homing
devices/ligands such as antibodies and cell
recognition proteins are usually linked onto the
particle surface. Various methods have been
employed to couple ligands to the surface of
the nanosized emulsions with reactive groups.
These can be divided into covalent and
noncovalent couplings. Noncovalent binding
by simple physical association of targeting
ligands to the nanocarrier surface has the
advantage of eliminating the use of rigorous,
destructive reaction agents and conditions.
Common covalent coupling methods involve
formation of a disulfide bond, cross-linking
between two primary amines, reaction between
a carboxylic acid group and a primary amine,
reaction between a maleimide and a thiol,
reaction between a hydrazide and an aldehyde,
and reaction between a primary amine and free
aldehyde (40). For antibody- conjugated anionic
emulsions, the reaction of the carboxyl
derivative of the coemulsifier molecule with
free amine groups of the antibody and disulfide
bond formation between coemulsifier
derivative and reduced antibody were the two
reported conjugation techniques (41-43).
However, by the formation of a thio-ether
bond between the free maleimide reactive
group already localized at the o/w interface of
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the emulsion oil droplets and a reduced
monoclonal antibody, the antibody-tethered
cationic emulsion was developed for active
targeting to tumor cells (44,45).
EMULSIFIERS TO STABILIZE THE O/W
NANOSIZED EMULSIONS FOR MEDICAL
APPLICATION 
In general, the o/w nanosized emulsion should
be formulated with compatible vehicles and
additives. The components of internal and
external phases of nanosized emulsion should
be chosen to confer enhanced solubility and
stability to the incorporated lipophilic drug. In
addition, the selected excipients should also
preferably be chosen to favorably influence the
biofate or therapeutic index of the incorporated
drug following administration via parenteral,
ocular, percutaneous, and nasal routes. This
section is a comprehensive presentation of the
general considerations concerning excipient
selection and their optimum concentrations. 
Prior to the formulation design of the
emulsions, data is needed concerning the drug
solubility in the oil vehicle. Additionally,
prerequisite information is needed about
compatibility of the oil vehicle with other
formulation additives and the established
ocular/skin tissues-oil vehicle matching before
the dosage form can be prepared. Table 1 lists
the common emulsion excipients and the oils
suitable for dissolving or dispersing lipophilic
drugs of ocular/parenteral interest. Since oils
are triglycerides, care must be taken to
minimize oxidation. Therefore, antioxidants
such as á-tocopherol (0.001-0.002% w/w) may
be included in a typical emulsion formulation
for medical applications. The final oil-phase
concentration in emulsions meant for ocular
use is now widely accepted to be at or below
5% w/w taking into account that the emulsion
must be kept in a low-viscosity range of
between 2 and 3 centipoises, which also is the
optimal viscosity for ocular preparations (46).
However, for all other medical uses, the
amount of oil may be varied but generally is
within 5-20% w/w. Sometimes, a mixture of
oils may be employed to facilitate drug
solubilization in the oil phase. Jumaa and
Müller (47,48) reported the effect of mixing
castor oil with medium chain triglycerides
(MCT) on the viscosity of castor oil. The oil
combination at the ratio of 1:1 (w/w) led to a
decrease in the viscosity of castor oil and
simultaneously to a decrease in the interfacial
tension of the oil phase. This phenomenon was
related to the free fatty acids contained in castor
oil, which can act as coemulsifiers, thereby
resulting in lower interfacial tension and,
simultaneously, in a more stable formulation in
comparison with the other oil phases. In
addition to the digestible oils from the family of
triglycerides, including soybean oil, sesame seed
oil, cottonseed oil, and safflower oil, which are
routinely used for making medical emulsions,
alternative biocompatible ingredients such as á-
tocopherol and/or other tocols were also
investigated for drug delivery purposes via o/w
emulsions (49,50). But the emulsions formed
from tocols are often considered as
microemulsion systems with few exceptions
(49,50).
Table 1 Common Excipients used for formulation of






Sesame oil Cholesterol Stearylamine ?- Tocopherol
Castor oil Phospholipids (Lipoid) Oleylamine Glycerin
Soyabean oil Polysorbate 80 and 20
(Tween 80 and 20)
Chitosan Xylitol  
Paraffin oil Transcutol P Sorbitol
Paraffin light Cremophor RH Thiomersal
Lanolin Poloxamer 407 EDTA
Vaseline  Poloxamer 188 Methyl paraben











U n l i k e  s p o n t a n e o u s l y  f o r m i n g
thermodynamically stable microemulsion
systems that require a high surfactant
concentration (20% and higher) and an alkanol
component, the kinetically stable nanosized
emulsions can be prepared by using relatively
lower surfactant concentrations. For example, a
20% o/w nanosized emulsion may only require
a surfactant concentration of 1-5%. The kinetic
stability of the nanosized emulsions can be
achieved by creating a barrier at the oil-water
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interface, protecting the emulsion from
breakage (7). These barriers may be of
electrostatic or steric nature and prevent
emulsion droplets from direct contact. The
most common way to stabilize emulsions is by
surfactant adsorbed at the interface between the
droplets and dispersion medium. Surfactant
adsorption layers do not only reduce the
interfacial tension but can also provide an
electrical charge to the emulsion droplets (ionic
surfactants) or create the strong steric barrier
via bulky molecular groups directed toward the
dispersion medium (non-ionic surfactants). 
Traditionally, lecithins or phospholipids are the
emulsifiers of choice to produce o/w nanosized
emulsions. However, additional emulsifiers
preferably dissolved in the aqueous phase are
usually included in the emulsion composition.
A typical example of the aqueous soluble
emulsifiers are nonionic surfactants (e.g.,
Tween 20) which are preferred because they are
usually less irritant than their ionic
counterparts. The nonionic block copolymer of
polyoxyethylene-polyoxypropylene, Pluronic
F68 (Poloxamer 188), is included to stabilize
the emulsion through strong steric repulsion.
However, surfactants such as Miranol MHT
( l a u r o a m p h o d i a c e t a t e  a n d  so d i u m
2tridecethsulfate) and Miranol C  M
(cocoamphodiacetate) were also used in earlier
ophthalmic emulsions (51). It should be added
that commercially available cyclosporin A-
loaded anionic emulsion (Restasis ) contains®
only polysorbate 80 and carbomer 1342 at
alkaline pH to stabilize the anionic emulsion.
To prepare a cationic emulsion, cationic lipids
(stearyl and oleylamine) or polysaccharides
(chitosan) are added to the formulation.
Strikingly, a stable emulsion based on chitosan-
lecithin combination was also reported (52).
Conversely, a cationic emulsion based on an
association of poloxamer 188 and chitosan
without the incorporation of lecithin was
prepared and also demonstrated adequate
stability (47,53). Recently, a report from our
group also indicated the stability of oil droplets
through the cation conferring chitosan along
with poloxamer 188 as a mixed emulsifier (54).
Since the free fatty acid generating
phospholipid emulsifier molecule is omitted
from the nanosized emulsion system, the stable
nanosized emulsion produced from chitosan-
poloxamer emulsifier combination has the
potential to attenuate a microclimate acidic pH
in the vicinity of oil phase, oil-water interface
and water phase of the emulsion (54). These
non-phospholipid-based emulsions should
therefore be able to incorporate the acid-labile
molecules like therapeutic peptides and
proteins, and to delineate the scope of applying
lyophilization process for the development of a
solid or dry emulsion. 
Oil in water emulsion compositions based on a
tocopherol (or a tocopherol derivative) as the
disperse phase has been described in a patent
granted to Dumex (55). Interestingly, the
emulsifying agent used to make tocol-based
emulsions is restricted to vitamin E TPGS (D-
alpha-tocopheryl polyethylene glycol 1000
succinate) presumably because adequate
toxicological data is not yet available for other
derivatives. According to a patent by Nakajima
et al (56), functional emulsions for use in food,
drugs and cosmetics were reported. These
emulsions were stabilized with various span
products such as span 80, span 40, etc. 
Advantages of charge stabilized
nanosized emulsions
 
At present, emulsions stabilized by positively
charged, cationic surfactants are most often
used as colloidal drug carriers (37). Kim et al
(57) used an emulsion of squalene in water
stabilized by the cationic surfactant 1,2-
dioleoyl-sn-glycero-3-trimethylammonium-
propane (DOTAP), which facilitated gene
transfer in biological fluid even in the presence
of 90% serum in the dispersion medium. The
emulsion droplets play the role of mucosal gene
carriers and can form stable complexes with
DNAs. Here the DNA was incorporated in the
emulsion by the de novo method. Compared
with liposomal carriers, cationic emulsions
demonstrated a 200 fold increase in
transfectional efficacy in both lungs and tissues
(57,58). The nature of oil as the disperse phase,
is another important factor that can affect the
applicability of such emulsions for transfection.
Three different oils were used for the disperse
phase: soybean oil, linseed oil, and squalene
(58). The transfection activities of the
nanosized emulsion carriers in the presence of
serum followed the order squalene > soybean
oil > linseed oil, and the squalene emulsions
were also most stable. From this data, the
authors concluded that stability of a carrier
system is a necessary requirement to form
This Journal is © IPEC-Americas Inc J. Excipients and Food Chem. 1 (1) 2010 - 18 
Review Paper
stable complexes with DNA, and this stability
determines the in vivo transfection.
The literature indicates that the interaction
between cationic liposomes and polyanionic
macromolecules like DNA is dependent on
their ratio, and at the ratio of maximum
transfection there occurs a prominent
aggregation phenomenon leading to
destabilization of formulation or desorption of
DNA from the formulation (59). Furthermore,
Simberg et al (60) suggest that an understanding
of the interplay between lipoplex composition,
its interaction with serum, hemodynamics and
target tissue properties (susceptibility to
transfection) could explain the biodistribution
and efficient in vivo transfection following
intravenous administration of cationic
lipid–DNA complexes (lipoplexes) in a murine
model. However, it is interesting to see what
could happen when the cationic nanoemulsion
is applied to in vitro cell culture models in the
presence of serum. The serum stability of
emulsion/DNA complex was reported (61).
Further studies are, however, necessary to be
carried out to understand clearly the origin of
the serum stability of this emulsion. In addition
the transfection efficiency of this emulsion was
not affected by time up to 2 h post-
emulsion/DNA complex formation. This
suggests that the o/w cationic nanosized
emulsion complexed with DNA is stable to
allow routine laboratory manipulation.
The o/w nanosized emulsions stabilized by
both cationic and anionic lipids were
investigated in order to compare the degree of
binding and uptake by specific cells that over-
e x p r e s s e d  t u m o r  r e c e p t o r s  ( 6 2 ) .
Immunoemulsions were prepared by
conjugating an antibody to the surfactant
molecule via a hydrophobic linker and then the
antibody-conjugated surfactant was used to
make the emulsion by the de novo method.
The anionic stabilized emulsions showed
decreased stability leading to phase separation
after 20 days of storage. The reduced stability
of anionic immunoemulsion could be attributed
to the rapid decrease of the zeta-potential
caused by the positively charged conjugated
antibody and consequently, due to a lower
electrostatic repulsion between the colloidal
droplets (62). On the other hand,
immunoemulsions stabilized by both anionic
and cationic emulsifiers exhibited a multifold
increase in cell binding in contrast to the
emulsions without antibodies. 
Positively charged o/w nanosized emulsions
were also found to be effective vehicles to
improve the skin permeability of incorporated
lipophilic molecules in dermatological
applications (63). Because epithelial cells of the
skin carry a negative surface charge they show a
high selectivity and permeability to positively
charged solutes. Thus, positively charged
nanosized emulsions are promising systems for
enhancing the skin permeability for drugs
included in the colloidal droplets. The authors
also showed that ceramides could be
successfully delivered transdermaly by means of
nanosized emulsions stabilized by a positively
charged interfacial layer of the naturally
occurring molecule, phytosphingosine. Other
applications of nanosized emulsions as carriers,
stabilized by ionic surfactants, in the
pharmaceutical and cosmetic fields have been
reviewed by Solans et al (64) and Tamilvanan
(65). 
Anionic phospholipids are also commonly
utilized for the stabilization of drug-carrying
nanosized emulsion droplets both individually
and in binary mixtures (66). Soybean lecithin
and modified phospholipid, n-hexanoyl
lysolecithin (6-PC), alone and as 1:1 mixtures
were used as stabilizers of medium-chain
triglyceride (MCT) droplets in water (66).
Although individual uncharged phospholipids
provide emulsion droplets with a moderate
negative charge for stabilization, mixed
phospholipids produce much more stable
emulsions and a large negative zeta-potential. A
possible explanation for this phenomenon is
related to the increased incorporation of polar
compounds from the soya lecithin into the
mixed interfacial film when 6-PC is present.
This interfacial film acts as a stabilizer by
forming a high energy barrier that repels
adjacent droplets and leads to the formation of
stabilized emulsified droplets. The stability of
the emulsion did not noticeably change, even in
the presence of the model destabilizing drug,
indomethacin, demonstrating the high potential
for such mixed emulsifiers for the formulation
of colloidal drug delivery systems (66).
Lysolecithin has one fatty acid ester chain
removed from the glycerol backbone, in
addition, lysolecithin is toxic (destroys RBC cell
membranes). Furthermore, although the role of
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phospholipids is essential for the stability of the
emulsions, possible cataractogenic effects due
to the phosphatidyl choline and, basically, to a
derivative of the same, lysophosphatidyl, have
been described by different authors (67,68). 
A new class of surface-active dialkyl maleates
can be utilized for emulsion polymerization
(69). Here, the emulsion droplets of monomeric
maleates are self-stabilized and simultaneously
serve as liquid “reactive storage carriers”. Three
types of head group in the dialkyl maleates were
studied- non-ionic, cationic, and zwitterionic
with different lengths of hydrophobic alkyl
chain. Cationic and zwitterionic dialkyl maleates
16 33with the longest alkyl chains - C H  and -
17 35C H  provided the best stability for o/w
nanosized emulsions. When compared with the
data obtained for the well-known non-ionic
10surfactant NPEO  (nonylphenol-poly (ethylene
oxide)) and the cationic CTAB (cetyltrimethyl
ammonium bromide), an excellent stabilizing
capacity especially for the cationic maleates can
be stated. Whereas non-ionic dialkyl maleates
show almost the same emulsifying ability and
10stability as NPEO , the cationic derivatives of
these novel surfactants are more effective in
stabilization than the traditional CTAB. 
Sometimes anionic surfactants are especially
added to emulsion droplets for the stabilization
of “reactive storage carriers” subjected to
further chemical transformation. Sodium
dodecyl sulfate (SDS) was utilized to stabilize
miniemulsion droplets which in the subsequent
step were polymerized and formed PBCA
(poly(n-butylcyanoacrylate)) nanoparticles,
suitable for targeting drug delivery to specific
cells (70). It is worth mentioning that SDS is
predominantly used to achieve required
miniemulsion stability (71). In some cases,
however, cationic surfactants are also used in
miniemulsion formulations, which were
reported first in the late seventies of the 20th
century. In general, however, stability of
miniemulsions does not depend on the sign of
the surfactant charge and is mainly determined
by the surfactant coverage of the reactive
carriers (miniemulsion droplets). The same
factor is also crucial for the size of
miniemulsion droplets after steady-state
miniemulsions are obtained (71).
Advantages of neutral-charged (sterically-
stabilized) nanosized emulsions
In many cases, however, greater emulsion
stability can be achieved without imparting a
significant surface charge to the emulsion
droplets, by means of steric stabilization (7).
Non-ionic surfactants possessing bulky
hydrophilic groups like polyoxyethylene (PEO)
protruding into the dispersion media decrease
coalescence arising from droplet collisions.
Another contribution to the steric stabilization
of emulsions by nonionic surfactants is
provided by the close packing of PEO chains at
the droplet surface. The compact packing of
PEO chains at the droplet surface creates
stearic stabilization because little or no
interpenetration of PEO chains on different
droplet surfaces occurs due to entropic
repulsion (72). Large head groups carrying
simultaneously charges of opposite signs, such
as in zwitterionic surfactants, can cause similar
effects. In polar dispersion media of low to
medium ionic strength, these groups are, as a
rule, strongly solvated (hydrated in the most
2common case of H O) (73). Voluminous and
on an average almost non-charged hydration
shells, surrounding the emulsion droplet
possess a significant steric rigidity and can also
effectively stabilize emulsions. There are,
however, only a few examples in the literature
that use zwitterionic surfactants as effective
emulsion stabilizers. For example, lecithin was
used for the stabilization of perfluorooctyl
bromide (PFOB) in water emulsions, to be used
as oxygen-carrying system in a bio-artificial liver
device (74). The Sauter mean diameter of 0.2
ìm PFOB emulsion droplet in water was
obtained by high-pressure homogenization. The
emulsion was stable for several months even at
a volume fraction of 20%. Non-ionic
surfactants are more often used for emulsion
stabilization than zwitterionic phospholipids
because they are synthetically manufactured,
can be well defined analytically and have
significantly less batch to batch variation than
naturally occurring (egg yolk, soybean) leci-
thins).  
The non-ionic surfactant Span-83, was used for
stabilizing water droplets in oil to form a
reactive storage carrier for the synthesis of
calcium carbonate nanoparticles by means of a
two membrane system (75). Firstly, an aqueous
emulsion was prepared in kerosene stabilized by
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30.02596 wt % Span and containing CO  ions
-2
in the droplets of the dispersed phase. The oil
phase contained also a 0.02792 M solution of
bis(2-ethylhexyl) hydrogen phosphate
(2DEHPA), a well-known molecular carrier for
the transportation of metal ions across
emulsion liquid membranes (ELM). In the
2second stage, a CaCl  aqueous solution filled
dialysis tube was placed into the oil-in-water
3emulsion and due to the reaction between CO
-
3 and Ca  ions in the aqueous droplets, CaCO
2 2+
nanoparticles were obtained. Similarly, ZnS
nanoparticles were prepared in inverse water-
oil-emulsion (76). The stabilization of
emulsions was provided by the addition of 5
wt% of Span 80 or Span 20, respectively, to the
oil phase (cyclohexane). The dispersed phase
contained a mixture of zinc acetate and
thioacetamide, which react upon heating to
form ZnS. The authors demonstrated that for
the preparation of ZnS nanoparticles the use of
Span 20 was more favourable because of the
smaller emulsion droplet size and therefore
lower and more homogeneous size of the final
particles. Another advantage was the higher
stability of Span 20 against hydrolysis as
compared to Span 80.
In general, fulfilling both stabilization
mechanisms (smaller droplet size and lesser
susceptibility of surfactant toward chemical
degradation) simultaneously leads not only to
the highest emulsion stability but also to lesser
sensitivity to changes in the external conditions
such as pH, ionic strength, and temperature.
Therefore the use of mixtures of different
classes of surfactants for emulsion stabilization
is frequently the most effective solution in
many practical cases.
Advantages of nanosized emulsions
stabilized by mixed or multicomponent
emulsifier molecules 
Sometimes mixtures of natural zwitterionic
surfactants used for emulsion stabilization
contain small amounts of polar compounds
which can be incorporated into the adsorption
layer and lead to a modest droplet charge which
additionally stabilizes the emulsion (65). Surface
layer with charged natural admixtures reported
by Trotta et al (66) is only a particular case of a 
very large class of emulsion-stabilizing systems
based on a tailored application of
ionic–zwitterionic surfactant mixtures. Mixtures
of dipalmitoylphosphatidylcholine (DPPC) and
homologues and dimyristoylphosphatidyl-
ethanolamine (DMPE) phospholipids were
utilized by Ishii and Nii (77) for stabilizing
model drug-carrying oil-in-water nanosized
emulsions. In contrast to the data, the main
stability factor was found to be the optimal
average hydrophilic-lipophilic balance (HLB)
value of the stabilizers mixture, defined
similarly for non-ionic surfactants (66). For
example, emulsions prepared with mixtures of
dimyristoylphosphatidylcholine (DMPC,
zwitterionic) and DMPE behaved similarly to
emulsions prepared by DMPC alone. This fact
was explained by the equivalence of HLB
values for both surfactants used, regardless of
their ionic nature. However, the ionic character
of a surfactant like DMPE (and therefore the
charge of respective emulsion droplets) can be
affected by the pH of the dispersion medium. 
The o/w nanosized emulsion stabilized by
mixed ionic/non-ionic surfactants revealed very
high physical stability and was found to be most
appropriate for dermatological applications as a
ceramide-carrying colloidal system (63). Greater
emulsion stability was achieved by the
combination of the non-ionic steric stabilizer
Tween 80 and the phospholipid co-stabilizers
phytosphingosine  and phosphatidyl-
ethanolamine. 
‘Stealth’ property of nanosized emulsions:
in vitro demonstrations 
Anionic emulsion formulations capture
apolipoproteins along with other plasma
proteins within minutes after an infusion in
human blood, facilitating their fast elimination.
In contrast, cationic emulsions reveal a much
longer retention time in the plasma, Moreover,
cationic colloidal carriers can promote the
penetration of therapeutic agents into cell
surfaces possibly via an endocytotic mechanism
(53). To improve the drug targeting efficacy of
colloidal carriers of anionic emulsions and to
further prolong the circulating effect of the
cationic emulsions, a mixed stabilizers film at
the oil/water droplet interface composed of
non-ionic Poloxamer 188 and ionic lipoid E80
and stearylamine/oleylamine was created
combining the effects of electrostatic and steric
barriers at the oil/water interface (78).
Competition between steric repulsion by
poloxamer and electrostatic attraction by ionic
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components led to the sensitive adsorption of
small molecular weight proteins like
apolipoproteins, albumins by the surface of
colloidal carriers whereas all emulsion droplets
were effectively shielded from the adsorption
of larger proteins like immunoglobulins,
fibrinogen, etc. enhancing the shelf-life of
emulsion formulations in the blood (Figure 3).
The apoA-I along with apoA-IV have been
suggested to modulate the distribution of apoE
between the different lipoprotein particles in
the blood and thereby affect their clearance
(78). In addition, the attachment of apoE would
greatly alter the in vivo distribution of fat
emulsions since this protein is a ligand for the
apoE-specific receptors on the liver
parenchymal cells. The higher the preferential
adsorption of apoA-I onto the cationic
emulsion droplets, the more intensified the
displacement/redistribution of apoE would,
therefore, be expected to occur on these types
of cationic emulsion formulations in the blood
(78). Indeed, the ratio of apoA-I to apoA-IV
was very close to 1 for Lipofundin  MCT 10%®
whereas it was about 0.26 for deoxycholic acid-
based anionic emulsion and above 5 for oleic
acid-based anionic emulsion and both cationic
emulsions.
Advantages of stabilizers in nanosized
emulsions
In some practical cases where emulsions are
applied under real, sometimes quite harsh
conditions, such as high temperature or shear
stresses, the stabilization of colloidal carriers by
conventional surfactants (ionic as well as non-
ionic) can appear to be insufficient to keep the
initially acceptable emulsion properties intact.
For ionic surfactants as stabilizers, the
stabilization mechanism based on the electrical
double layer fails at high amounts of electrolyte.
The situation for non-ionic surfactants as
stabilizers is only slightly better because their
molecules are typically not strongly adsorbed
(79,80). Therefore, the most effective way to
stabilize emulsions by creation of a protective
adsorption layer is the use of amphiphilic
macromolecular compounds or polymeric
surfactants (79). In contrast to the commonly
used monomolecular surfactants, polymeric
surfactants do not only adsorb much stronger
but also retain this ability under high electrolyte
concentration or/and high temperature (79,80).
This is made possible due to a special molecular
design of surface active polymers which have in
their structure anchor groups responsible for
strong adsorption at the interface and
stabilizing groups protruding from the interface
into the dispersion medium and forming a
bulky layer with thicknesses of several
nanometers.
Most often used stabilizers for the preparation
of emulsions, in the fields of agrochemicals,
pharmaceuticals and personal care products, are
either block or graft copolymers. In block
copolymers, the hydrophobic blocks reside at
the surface or even partly penetrate in the oil
droplet, making trains or short loops whereas
the hydrophilic blocks protrude in the
dispersion medium as loops or tails providing
steric stabilization (80). As examples, PEO-
PPO-PEO triblock copolymer (commercially
available as “Pluronics”) or PPO-PEO-PPO
can be mentioned. Triblock copolymers are,
however, not the most efficient stabilizers
because the PPO chain is not hydrophobic
enough to attach strongly at the o/w interface
(81). The surface activity of these polymeric
surfactants is rather the result of a rejective
anchoring or negative enthalpic energy change
of the PPO group because of its low solubility
in water and most oils. Alternative and more
efficient graft copolymers consist of a
polymeric backbone attached to the interface
and several chains dangling into the continuous
phase and forming at the interface a “brush”
structure.
Figure 3 Amount of major proteins on the 2-D gels of
plasma proteins adsorbed on emulsions with negative or
positive surface charge in comparison with Lipofundin
MCT 10% [by permission from Elsevier (61)].
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A typical example of commercial graft was
described (82) .  Here,  mixtures of
Polyoxyethylene-660-12-hydroxystearate
(Solutol HS15) with the anionic lipid
composition Lipoid S75 were employed to
enhance the long term as well as accelerated (by
freezing and centrifugation) stability of oil-in-
water nanosized emulsions. Emulsion stabilized
by phospholipids displayed a stable behaviour
after autoclaving and centrifugation but de-
emulsified after freezing. In contrast, emulsions
prepared only with Solutol HS15 demonstrated
a significant change in particle size after
autoclaving. The best results were obtained
using a stabilizer mixture revealing a
combination of electrostatic stabilization
mechanism typical for the anionic
phospholipids and the steric stabilization
mechanism originating from non-ionic
polymeric surfactant. The combination of
stabilization mechanisms improved the
emulsion's stability, compared to the emulsion's
stability prepared using only the individual
surfactants. 
The commercially available cationic block-
copolymer Eudragit E100 was utilized as both
emulsion stabilizer and solidifying agent upon
further drying (83). Due to the specific
properties of Eudragit E100, no surfactant or
organic solvent additives were employed in
order to fulfil common ecological,
toxicological, and manufacturing safety
requirements during the preparation of a
redispersible dry emulsion. 
The naturally occurring polymers cyclodextrins
are commonly used in pharmaceutical aqueous
formulations for inclusion of less soluble or
instable drugs. Their use, however, is
complicated by poor interaction with biological
membranes. To overcome this difficulty, the
cyclodextrins were chemically modified,
including grafting of fatty acid chains to the
hydroxyl groups in order to provide the
optimum surface activity to the polymer (84).
Upon addition of Miglyol to an aqueous phase,
nanocapsules with an oily interior were formed
spontaneously. These nanocapsules had an
average size of approximately 300 nm and
revealed an excellent long-term stability for at
least 5 months. Interestingly, the most
appropriate properties for nanocapsules
formation were observed for cyclodextrin
6derivatives with linear C  chains. Compounds
possessing longer aliphatic chains caused the
formation of large polydisperse aggregates and
were therefore unsuitable for encapsulation.
The preparation of nanocapsules with modified
cyclodextrins without the addition of
surfactants is a promising tool for the
development of novel drug delivery systems. A
variety of current approaches to increase
emulsion stability with help of emulsifier
molecules have been summarized in a recent
review by Grigoriev and Miller (85).
Miscellaneous additives
Additives other than antioxidants such as
preservatives (e.g., benzalkonium chloride,
chlorocresol, parabens) are included in
emulsions to prevent microbial spoilage of
multidose medical emulsions. á-Tocopherol is a
good example of an antioxidant used to obtain
a desirable stabilized emulsion under prolonged
storage conditions. The presence of
components of natural origin such as lecithin or
oils with high calorific potential renders the
emulsion a good medium to promote microbial
growth when it is packaged in multidose
containers. Pharmaceutical products when
distributed into multidose containers, especially
for parenteral and ocular administrations,
should be properly preserved against microbial
contamination and proliferation during storage
under normal conditions and proper use.
Incorporation of preservatives in single-dose
vials is also a common procedure if filtration is
used as a sterilization method (65). Sznitowska
et al (86) studied the physicochemical
compatibility between the lecithin - stabilized
emulsion and 12 antimicrobial agents over two
years of storage at room temperature.
Preliminary physicochemical screening results
indicated that the addition of chlorocresol,
phenol,  benzyl alcohol,  thiomersal ,
chlorhexidine gluconate, and bronopol should
be avoided due to the occurrence of an
unfavorable pH change followed by
coalescence of lecithin-stabilized droplets of the
emulsion. 
Furthermore, the efficacy of antimicrobial
preservation was assessed using the challenge
test according to the method described by the
European Pharmacopoeia.
Despite good physicochemical compatibility,
neither the parabens nor benzalkonium
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chloride showed satisfactory antibacterial
efficacy in the emulsion against the tested
microorganisms and consequently were not
suitable for preservation. Therefore, higher
concentrations of antimicrobial agents or their
combinations may be required for efficient
preservation of the lecithin-stabilized emulsion
probably because of unfavorable phase
partitioning of the added antimicrobials within
the different internal structures of the emulsion
(86). This finding clearly indicates that the
possible electrostatic attraction between the
negatively charged lipid moieties of the mixed
emulsifying film formed around the anionic
emulsified oil droplets (69) and the quaternary
cationic ammonium groups of the preservative
is not the plausible cause for the reduced
activity of the benzalkonium chloride. Thus, the
possible intercalation of this surfactant in either
the cationic or anionic interfacial mixed
emulsifying film is likely to occur, preventing
benzalkonium chloride from eliciting its
adequate preservative action (86). 
For the development of cationic emulsions in
ophthalmology, the use of quaternary
ammonium compound (QAC) for their cationic
property rather than their preservative effect is
being considered. Therefore, Liang et al (87)
suggested the use of lipophilic cetalkonium
chloride (CKC), one of the longest alkyl-chain
components, as a cationic agent in ophthalmic
emulsions. With a highly lipophilic QAC, the
distribution between the oil and aqueous phases
of the emulsion is modified because of the
affinity toward the oil phase, further favoring
the cationic agent role over the preservative
role. Using in vivo confocal microscopy
(IVCM) for in vivo tissues images and
impression cytology (IC) for ex vivo epithelium
inflammatory marker expression in correlation
with standard immunohistology for deep
infiltration and apoptosis, the same author
assessed the toxicological effects of
b e n z a l k o n i u m  c h l o r i d e / C K C
emulsion/solution formulations on the ocular
surface of rabbits following multiple topical
applications (87). These in vivo and ex vivo
experimental approaches demonstrated that
ocular surface toxicity was reduced by using an
emulsion instead of a traditional solution and
that a CKC emulsion was safe for ocular
administration. 
Overall, it is preferable to formulate nanosized
emulsions devoid of preservative agents and fill
it in sterile single-dose packaging units to
prevent potential contamination. It should be
pointed out that the two available ocular
emulsion products (Refresh Endura  and®
Restasis , Allergan, Irvine, CA) on the market®
are preservative free and packed in single-use
vials. Currently there is no commercial
parenteral emulsion which contains
preservatives and research concerning the
problem of preservation of nanosized emulsion
is very limited (88-91). 
C U R R E N T  A N D  N E A R  F U T U R E
DIRECTION
Colloidal particles stabilized emulsions
In addition to surfactants, polymers and
biomolecules, colloidal particles have long been
recognised to stabilise droplets, e.g. as in
Pickering emulsions (92). Examples of various
colloidal particle types used to stabilize
4emulsions include BaSO , crystalline ferric
oxide, carbon black, bentonite, kaolinite clay,
latex, and silica particles. The effectiveness of
emulsion stabilisation by particles depends on
the particle size, shape, concentration, and
wettability (expressed as the contact angle at the
three phase boundary and is equivalent to the
hydrophile-lipophile balance (HLB) of a
surfactant), as well as the level of particle
aggregation as controlled by particle-particle
interaction (93). It is proposed that the
conventional model for emulsion stabilisation
by solid particles assumes the formation of a
‘‘densely packed’’ layer at the oil-water
interface, which prevents droplet coalescence
by a steric barrier mechanism. If charged,
particles may give rise to electrostatic repulsion,
which further enhances emulsion stability.
Many commercial products based on emulsions
(for cosmetic and food uses) include both
surfactants and particles, hence the
characterisation and mechanisms of
stabilisation for emulsions with mixed
interfacial layers are of great importance (94).
These droplet/surfactant/particle systems are
also of interest in designing low-surfactant
emulsion systems with enhanced stability (95).
Tambe and Sharma (96) reported the
improvement in the stability of emulsions
stabilised with calcium carbonate particles
following the addition of stearic acid. This
synergistic effect was attributed to the
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adsorption of surfactant on solid particles
resulting in the change in particle wettability. A
strong emulsification synergy in stabilising o/w
emulsions between hydrophilic colloidal silica
(Ludox) and non-ionic polyoxyethylene
surfactants added from the water phase has
been demonstrated by Midmore (95). The
synergy was attributed to the POE micellar
adsorption or POE chain bridging between
silica particles which resulted in better
interfacial adsorption. Synergistic stabilisation
of oil-in-water emulsions by a mixture of non-
ionic surfactants and hydrophilic silica
nanoparticles has recently been studied by
Binks et al (94) highlighting the importance of
preparation protocol. Attachment energy of a
silica particle at the oil-water interface was
correlated to emulsion stability. Velev et al (97)
reported that the adsorption of lysine onto
negatively charged latex particles enabled
interfacial adsorption due to the reduction of
hydration forces and electrostatic repulsion
between droplets and particles. The influence
of droplet-particle electrostatic interactions on
emulsion stability was studied by Lan et al (98)
and Binks and Whitby (99). Addition of
cationic surfactant CTAB to negatively charged
hydrophilic silica dispersions as the aqueous
phase of emulsions, resulted in enhanced
stability at low CTAB concentrations, i.e. the
region where CTAB is preferably adsorbed
onto silica surface and promoted interfacial
adsorption due to neutralisation of surface
charge and optimisation of particle
hydrophobicity. This synergistic emulsion
stabilization comes from three sources: CTAB
(i) hydrophobizes silica nanoparticles by partial
charge neutralization, (ii) promotes nanoparticle
aggregation, and (iii) reduces interfacial tension.
However, when the CTAB concentration is
such so that both droplets and silica surfaces
are positively charged, emulsion stability is
significantly reduced. 
Simovic and Prestidge (100) showed that
nanoparticle layers significantly influence the
release kinetics of a model lipophilic drug (di-
b u t y l - p h t h a l a t e  ( D B P ) )  f r o m
polydimethylsiloxane o/w emulsions; either
sustained or enhanced release can be achieved
depending on the nanoparticle layer structure
and drug loading level. Nanoparticle layers can
be engineered to facilitate a range of release
behaviours and offer great potential in the
delivery of poorly soluble drugs. Particle
stabilised emulsions have been extensively
studied in terms of stabilisation mechanisms
(99,101), synergy with common emulsifiers (98,
102), and interfacial properties (103,104).
However, few reports have focused on their
carrier properties as dermal delivery vehicles,
e.g. penetration and targeting skin layers.
Recently, the influence of nanoparticle coating
of submicron (nanosized) oil-in-water emulsion
droplets on the in vitro release and dermal
delivery characteristics, with particular emphasis
on potential controlled release and targeted skin
delivery of all-trans-retinol was reported by
Eskandar et al (105). Medium-chain triglyceride
o/w emulsions have been stabilised with mixed
interfacial layers composed of lecithin or
oleylamine and hydrophilic silica nanoparticles
using a simple cold high pressure
homogenization technique. These emulsion
based hybrid drug delivery systems showed
improved topical delivery of all-trans-retinol;
nanoparticle layers significantly improved the
performance of o/w emulsions as
encapsulation and delivery systems for all-trans-
retinol. Therefore, emulsion-based hybrid drug
delivery systems should have a potential for
drug delivery.  
CONCLUSION 
The preparation by de novo method or
SolEmul  technology allows the production of®
emulsion particles in nanosized range with
acceptable stability without the separation of oil
and water phases. Based on the conferration of
surface/interfacial charges by the incorporation
of selective excipients onto the emulsion
systems, the o/w nanosized emulsions can
conveniently be classified into neutral, anionic
and cationic. Whereas the ionic emulsifier can
impart repulsive forces between similarly
charged electrical double layers to emulsified oil
droplets, the non-ionic emulsifier can provide
the interactive particles with the steric
stabilization. Furthermore, addition of
particular excipients to the emulsion system
prevents the opsonization of emulsion particles
and thus increases substantially the circulation
time of emulsion particles inside the
bloodstream for reaching the intended target
site in vivo.  Accumulating knowledge thus
suggests that constant progress in better
understanding the principles and processes
governing the various issues related to o/w
nanosized emulsions has brought major
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improvements in the efficacy of parenteral or
nonparenteral drug delivery systems.
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LIST OF ABREVIATIONS
CTAB cetyltrimethyl ammonium bromide
CKC cetalkonium chloride







EDTA ethylenediamine tetraacetic acid 
ELM emulsion liquid membranes 
HLB hydrophilic-lipophilic balance 
HP high-pressure 
HPH high pressure homogenization 
IC impression cytology 
IVCM in vivo confocal microscopy 
MCT medium-chain triglyceride 
NPEO10 nonylphenol-poly (ethylene oxide) 
O/w- oil-in-water 
PBCA poly(n-butylcyanoacrylate) 
6-PC- n-hexanoyl lysolecithin 
PEO polyoxyethylene 
PFOB perfluorooctyl bromide 
QAC quaternary ammonium compound 
SDS Sodium dodecyl sulfate
Solutol HS15 Polyoxyethylene-660-12-hydroxystearate 
TPGS D-alpha-tocopheryl polyethylene glycol 1000
succinate 
UHPH ultra-high pressure homogenization. 
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